Posted by Michael Wonder on 21 Jan 2025
Immunotherapy Qarziba to be reimbursed for high-risk neuroblastoma patients starting next month
28 November 2024 - The treatment landscape for neuroblastoma, the most common cancer in children outside of blood and brain tumors, is set to improve.
Starting next month, the immunotherapy drug Qarziba (dinutuximab beta), a critical treatment option for high-risk and relapsed/refractory neuroblastoma patients, will be covered by health insurance in Korea.
